Companies betting big on biotech solutions for Zika, antibiotic resistant bacteria

[The overuse of antibiotics has] become a real problem: antibiotic-resistant pneumonia rates currently exceed 50% in the U.S. Clearly, there’s a huge need for new therapies.

Cempra is one company focused on finding a solution. The company’s lead compound is called solithromycin, and it’s currently pending FDA approval as a treatment for community-acquired bacterial pneumonia, or CABP.

Developing an effective vaccine to prevent Zika virus infection could take years. In the meantime, efforts to cull populations of the infamous Aedes aegypti mosquito…may get a boost from Intrexon.

[L]ast September it made a bold $146.4 million acquisition of Oxitec and its genetically engineered self-limiting mosquito technology…It almost sounds too easy, but data from a pilot program in the city of Piracicaba, Brazil, are highly encouraging.

[GlaxoSmithKline] recently decided to depart from its traditional approach to product development, by announcing a bold joint venture with Verily Life Sciences…to create the first generation of bioelectronic medicines for chronic diseases.

While this moonshot effort is still in its infancy…this foray into bioelectronic medicine is well worth checking out….

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. Read full, original post: 3 Bold Bets on the Future of Biotechnology

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend